Theravance Biopharma (NASDAQ:TBPH) Stock Price Up 8.8% – Should You Buy?

Theravance Biopharma, Inc. (NASDAQ:TBPH) shares rose 8.8% during trading on Friday . The stock traded as high as $10.38 and last traded at $10.52. Approximately 145,699 shares traded hands during mid-day trading, a decline of 17% from the average daily volume of 174,689 shares. The stock had previously closed at $9.67.

Theravance Biopharma Trading Up 8.3 %

The stock’s 50-day simple moving average is $9.47 and its two-hundred day simple moving average is $8.92.

Theravance Biopharma (NASDAQ:TBPH) last released its earnings results on Tuesday, November 12th. The biopharmaceutical company reported ($0.26) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.16). Theravance Biopharma had a negative net margin of 78.18% and a negative return on equity of 24.79%. The business had revenue of $16.87 million during the quarter, compared to analyst estimates of $16.11 million. During the same period last year, the business earned ($0.17) EPS. Equities analysts expect that Theravance Biopharma, Inc. will post -1.09 earnings per share for the current year.

Insider Activity at Theravance Biopharma

In related news, SVP Rhonda Farnum sold 4,000 shares of Theravance Biopharma stock in a transaction dated Tuesday, January 21st. The stock was sold at an average price of $9.00, for a total value of $36,000.00. Following the completion of the transaction, the senior vice president now directly owns 309,565 shares of the company’s stock, valued at $2,786,085. The trade was a 1.28 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. 6.90% of the stock is currently owned by insiders.

Institutional Trading of Theravance Biopharma

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Quantbot Technologies LP bought a new position in Theravance Biopharma during the third quarter worth about $60,000. China Universal Asset Management Co. Ltd. lifted its holdings in shares of Theravance Biopharma by 64.7% during the third quarter. China Universal Asset Management Co. Ltd. now owns 9,409 shares of the biopharmaceutical company’s stock worth $76,000 after buying an additional 3,696 shares in the last quarter. Ballentine Partners LLC acquired a new stake in shares of Theravance Biopharma in the third quarter valued at approximately $104,000. Hsbc Holdings PLC bought a new stake in Theravance Biopharma during the second quarter worth about $108,000. Finally, XTX Topco Ltd acquired a new stake in shares of Theravance Biopharma in the 2nd quarter valued at $129,000. 99.10% of the stock is owned by institutional investors.

Theravance Biopharma Company Profile

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.